Myriad Genetics validates polygenic risk score for breast cancer
Category: #health  By Mateen Dalal  Date: 2019-12-16
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Myriad Genetics validates polygenic risk score for breast cancer

Myriad Genetics, Inc., a company focused on precision medicine and molecular diagnostics, has reportedly presented the result of a new validation study of its polygenic risk score (PRS) for breast cancer at the 2019 San Antonio Breast Cancer Symposium in San Antonio, Texas. 

The result showed that the PRS substantially enhances the accuracy and precision of breast cancer risk evaluations for women of European ancestry with PV (pathogenic variants) in moderate- and high-penetrance breast cancer genes.

Jerry Lanchbury, Ph.D., Chief Scientific Officer, Myriad Genetics, said that the company’s goal is to help women in understanding the risk of breast cancer so that they can take proactive steps to healthier and longer lives. Females who have a family record of breast cancer should think about hereditary cancer testing with the myRisk Hereditary Cancer test, said Lanchbury.

Moreover, the study showed that for women, who are tested positive for a mutation in one of the five breast cancer genes, own added genetic factors termed single nucleotide polymorphisms (SNPs) that can further aid the lifelong risk of breast cancer.

As for Elisha Hughes, Ph.D., Lead Investigator and Director of Bioinformatics at Myriad Genetics, said that these findings signal that the company has the potential to considerably enhance the precision of hereditary cancer risk evaluation for females who test positive for mutations in intermediate to high-risk breast cancer genes.

Hughes added that this additional genetic information could help clinicians to accurately and precisely predict breast cancer risk and offer the best care for their patients in the future.

Sources further inform that Myriad Genetics, following this announcement, plans to publish these new data in a peer reviewed medical journal and make PRS available for U.S. women of European ancestry, who are tested positive for mutations in breast cancer genes.

Currently, the PRS is available as part of the Myriad myRisk® Hereditary Cancer improved with riskScore® for women of European ancestry who exam negative for pathogenic mutations in breast cancer genes. 
 

Source Credit - https://myriad.com/investors/news-release/news-release-detail/?newsItemId=20921

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

EVs could capture 50% revenue share of major markets by 2030: Report

EVs could capture 50% revenue share of major markets by 2030: Report

By Mateen Dalal

According to a report provided by KPMG, more than 50% of the total vehicle sales will be controlled by the EV segment by 2030. Electric vehicles are rapidly gaining a large share in the mainstream global automobile market. With electric two-wheelers...

Tesla app outage led to several drivers being locked out of their cars

Tesla app outage led to several drivers being locked out of their cars

By Mateen Dalal

Several owners took to social media to vent out as they were unable to utilize their vehicles due to the app outage. CEO Elon Musk has apologized and guaranteed that it does not re-occur in the future. Several Tesla owners were reportedly una...

EU lawmakers agree on new terms for regulating Big Tech companies

EU lawmakers agree on new terms for regulating Big Tech companies

By Mateen Dalal

European Union lawmakers have reportedly settled on new terms for targeting Big Tech companies, an effort to reduce anti-competitive practices in the digital world. According to sources, major political parties in the European Parliament agreed to a...